

GODAVARI DRUGS LIMITED

Regd. Off.:'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India. Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557 E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

Date: 12.11.2021

To, The General Manager, Listing Department, Bombay Stock Exchange 1st Floor, New trading Wing, Rotunda Building, P.J. Towers, Dalal Street Fort, Mumbai-400001

Dear Sir/Madam,

Sub: Financial Results for quarter ended 30.09.2021-Regulation 33

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting through Video Conferencing held on Friday, 12th November, 2021 at 11:00 A.M, interalia considered and approved the unaudited Financial Results for the quarter ended 30th September, 2021

Copy of Unaudited Financial Results for the quarter ended 30.09.2021 is enclosed herewith

Kindly take the same on record and acknowledge the receipt of same.

Thanking You For Godavari Drugs Limited SEC'BAD Rashmi Agarwal Company Secretary & Comphance Officer



Independent Auditor's Review Report on unaudited quarterly financial results of Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors . Godavari Drugs Limited

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and six months ended September 30, 2021 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Sridhar & Co., Chartered Accountants FRN: 0062065

Vard

Vemulapati Sridhar Proprietor ICAI Membership No. 202337 Hyderabad. November 12, 2021. UDIN: 21202337AAAADT5366.



GODAVARI DRUGS LIMITED CIN NO.L24230TG1987PLC008016 Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2021

							(Rs. In Lakhs)
SI.		Quarter ended		Half Year Ended		Year ended	
N Particulars		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
0.		(Unaudited) 3866.67	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	Revenue from operations		4440.18	3092.03	8306.85	5661.25	12267.01
2 Other Income		9.05	1.70	20.50	10.75	21.43	41.01
3 Total Revenue from opera	ations (1+2)	3875.72	4441.88	3112.53	8317.60	5682.68	12308.02
4 Expenses							State of the state of the
(a) Cost of materials co	sumed	3290.26	3663.10	2488.37	6953.36	4873.77	9414.80
	pries of finished goods &	-197.50	-87.75	-13.28	-285.25	-409.01	244.02
work-in-progress (c) Employee benefits	expense	132.29	118.14	89.57	250.43	167.35	394.31
(d) Depreciation & am		42.53	41.75	28.13	84.28	55.98	122.27
	offization expense	78.52	71.26	83.17	149.78	168.05	330.80
(e) Finance Costs (f) Other Expenses		351.26	437.07	284.95	788.33	560.01	1231.18
Total expenses		3697.36	4243.57		7940.93	5416.15	11737.38
5 Profit before exceptional	Itoms and tax (3-4)	178.36	198.31	151.62	376.67	266.53	570.64
	items and tax (3-4)		100.01				
6 Exceptional items 7 Profit before Tax (5-6)		178.36	198.31	151.62	376.67	266.53	570.64
		-56.23	-55.88		-112.11	-82.62	-157.83
8 Tax expense	7.0)	122.13	142.43	98.84	264.56	183.91	412.81
9 Net Profit for the period (122.10	112.10	00.04	201.00	100.01	
10 Other Comprehensive Inc							
	be reclassified to profit or loss						
	g to Items that will not be						
	reclassified to profit or loss						
				100000000			
	g to Items that will be						
(iv) reclassified to prof 11 Total Comprehensive Inc		122.13	142.43	98.84	264.56	183.91	412.81
12 Paid-up equity share capita		122.10	112.10				
(Face Value Rs. 10/- per sh		753.05	753.05	753.05	753.05	753.05	753.05
13 Other Equity(Reserves and		100.00				1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	1685.56
				Charles and	1.2		
14 Earnings per share (of Rs.10/- each) (not and	nualized)						
		1.62	1.89	1.31	3.51	2.44	5.48
(a) Basic (b) Diluted		1.62	0.020			2.44	5.48
		1102	1				

Notes:

1. The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 12th November 2021.

2. The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable

3. The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.

4. Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

1c. 1c. K.K.Jain

K.K.Jain Director Finance DIN: 00076657

Place: Secunderabad Date: 12.11.2021 inance 6657 DA

SEC'BA

GODAVARI DRUGS LIMITED CIN NO.L24230TG1987PLC008016 Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

Statement of Assets and Liabilities

	Half Year ended	(Rs. in Lakhs)	
Particulars	(30.09.2021)	Year ended (31.03.2021)	
	(Unaudited)	(Audited)	
ASSETS			
1. Non - current assets			
a. Property, plant and equipment	2160.03	2,243.47	
b. Capital work - in -progress	238.33	75.77	
c. Investment Property			
d. Goodwill			
e. Other Intangible assets			
f. Intangible assets under development			
g. Biological Assets other than bearer plants			
h. Financial Assets			
(i) Investments	0.01	. 0.01	
(ii) Trade Receivables			
(iii) Loans			
(iv) Others			
i. Deferred tax assets (net)			
j. Other non-current assets	33.56	33.38	
2. Current assets			
(a) Inventories	1941.58	1465.00	
(b) Financial Assets			
(i) Investments			
(ii) Trade Receivables	5484.28	4512.1	
(iii) Cash and cash equivalents	214.66	163.8	
(iv) Bank balances other than (iii) above			
(v) Loans	54.68	56.73	
(vi) Others			
(c) Current Tax Assets (Net)			
(d) Other current assets	514.35	563.6	
Total Assets	10641.48	9113.9	
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity Share capital	753.05	753.0	
(b) Other Equity	1950.13	1685.5	
(i) Reserves and surplus			
Non controlling interest			
LIABILITIES			
1. Non - current liabilities			
(a) Financial Liabilities			
(i) Borrowings	1517.22	1448.9	
(ii) Trade payables			
(iii) Other financial liabilities (other than			
those specified in item (b)			
(b) Provisions	83.56	78.68	
(c) Deferred tax liabilities (Net)	114.52	96.5	
(d) Other non-current liabilities			
2. Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	1471.23	1358.8	
(ii) Trade payables	4222.50	2950.4	
(iii) Other financial liabilities (other than			
those specified in item (c)	401.56	623.0	
(b) Other current liabilities	33.59		
(c) Provisions			
(d) Current Tax Liabilities (Net)	94.12	118.8	
Total Equity and Liabilities	10641.48	9113.9	

For GODAVARI DRUGS LIMITED

Place: Secunderabad Date : 12.11.2021 IC. JC. Jam K.K.Jain Director Finance DIN: 00076657



Godavari Drugs Limited Cash Flow Statement for the Half Year ended September 30,2021.

Particulars	Period ended 30.09.2021	Previous Year 2020-21
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	610.74	1,023.71
Other income considered separately	(10.75)	(41.01)
Net	599.98	982.69
(Increase) / Decrease in Inventories	(476.58)	310.20
(Increase) / Decrease in Receivables	(972.17)	(910.26)
(Increase) / Decrease in Short term Loans & Advances	2.06	(7.26)
(Increase) / Decrease in Other Current Assets	49.32	(50.13)
Increase / (Decrease) in Current Liabilities	1,189.81	(34.64)
Less: Income tax paid	(94.11)	(118.80)
Less: Deferred Tax Adjustment	(18.00)	(39.03)
Total A	280.32	132.78
B. Cash Flow from Investing Activities		
Increase in Fixed Assets and Capital WIP	(163.39)	(167.20)
Increase in Non Current Assets	(0.18)	1.17
Other Income	10.75	41.01
Total B	(152.82)	(125.01)
C. Cash Flow from Financing Activities		
Increase / (Decrease) in Long Term Borrowings	68.24	332.62
Increase / (Decrease) in Long Term Provisions	4.88	11.58
Increase / (Decrease) in Long Term Advances		
Interest Paid	(149.78)	(330.80)
Total C	-76.66	13.40
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	50.83	21.17
Cash and cash equivalents at the beginning of the year (01.04.2021)	163.83	142.66
Cash and cash equivalents at the end of the year (30.09.2021)	214.66	163.83
Increase/(-)Decrease	50.83	21.17

For GODAVARI DRUGS LIMITED

K...k.Jain K.K.Jain Director Finance DIN: 00076657



Place: Secunderabad Date : 12.11.2021